BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 22282465)

  • 21. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
    Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
    Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
    Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
    J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
    Xu J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
    Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA
    J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.
    Liu NN; Ohkouchi M; Hashikura Y; Kajimoto N; Matsuda I; Isozaki K; Toh Y; Takahashi T; Nishida T; Hirota S
    Lab Invest; 2013 May; 93(5):502-7. PubMed ID: 23459373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
    Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
    Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors.
    Celestino R; Lima J; Faustino A; Vinagre J; Máximo V; Gouveia A; Soares P; Lopes JM
    Eur J Hum Genet; 2013 May; 21(5):503-10. PubMed ID: 22948025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
    Zhi X; Zhou X; Wang W; Xu Z
    PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KIT mutations in GIST.
    Fletcher JA; Rubin BP
    Curr Opin Genet Dev; 2007 Feb; 17(1):3-7. PubMed ID: 17208434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
    Gounder MM; Maki RG
    Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
    Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.
    Li S; Zhao S; Liang N; Zhang S; Zhang L; Zhou L; Liu A; Cao X; Tian J; Yu Y; Fan Z; Xiao K; Wang M; Zhao H; Bai R; Sun J
    Gastric Cancer; 2023 Sep; 26(5):677-690. PubMed ID: 37222910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
    Heinrich MC; Corless CL; Blanke CD; Demetri GD; Joensuu H; Roberts PJ; Eisenberg BL; von Mehren M; Fletcher CD; Sandau K; McDougall K; Ou WB; Chen CJ; Fletcher JA
    J Clin Oncol; 2006 Oct; 24(29):4764-74. PubMed ID: 16954519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated?
    Jašek K; Váňová B; Grendár M; Štanclová A; Szépe P; Hornáková A; Holubeková V; Plank L; Lasabová Z
    Pathol Res Pract; 2020 Nov; 216(11):153171. PubMed ID: 32836055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activate and resist: L576P-KIT in GIST.
    Conca E; Negri T; Gronchi A; Fumagalli E; Tamborini E; Pavan GM; Fermeglia M; Pierotti MA; Pricl S; Pilotti S
    Mol Cancer Ther; 2009 Sep; 8(9):2491-5. PubMed ID: 19723893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
    Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
    Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.